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Cost-effectiveness of memory assessment services for the diagnosis and early support of 
patients with dementia. 
 
Abstract 
Background 
Policy makers in England advocate referral of patients with suspected dementia to Memory 
Assessment Services (MAS) but it is unclear how any improvement in patients’ health-related 
quality of life (HRQL) compares with the associated costs. 
Aims 
To evaluate the cost-effectiveness of MAS for the diagnosis and follow-up care of patients 
with suspected dementia.  
Method 
We analysed observational data from 1318 patients referred to 69 MAS, and their lay carers 
(n=944), who completed resource use and HRQL questionnaires at baseline, three and six 
months. We reported mean differences in HRQL (disease-specific DEMQOL and generic 
EQ-5D-3L), quality-adjusted life years (QALYs) and costs between baseline and 6 months of 
referral to MAS. We also assessed cost-effectiveness of MAS across different patient 
subgroups and clinic characteristics. 
Results 
Referral to MAS was associated with gains in DEMQOL (mean gain 3.48, 95% confidence 
interval: 2.84 to 4.12), EQ-5D-3L (0.023, 0.008 to 0.038) and QALYs (0.006, 0.002 to 0.01).  
Mean total costs over six months, assuming a societal perspective, was £1,899 (£1277 to 
£2539). This yielded a negative incremental net monetary benefit, -£1724 (-£2388 to -£1085) 
assuming NICE’s recommended willingness-to-pay threshold (£30,000 per QALY). These 
base case results were relatively robust to alternative assumptions about costs and HRQL. 
There was some evidence that patients aged 80 or older benefitted more from referral to MAS 
(p<0.01 from adjusted mean differences in net benefits) compared to younger patients. MAS 
with over 75 new patients a month or cost per patient less than £2500 were relatively more 
cost-effective (p < 0.01) than MAS with fewer new montly patients or higher cost per 
patient, respectively. 
Conclusions 
Diagnosis, treatment and follow-up care provided by MAS to patients with suspected 
dementia appears to be effective, but not cost-effective over the first six months after 
diagnosis. Longer-term evidence is required before drawing conclusions about the cost-
effectiveness of MAS. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Dementia is a major cause of disability and poor quality of life for older people and their 
families, and is associated with rising health care costs worldwide (1). In England, the 
number of people with dementia is growing fast and expected to reach 1 million in the next 
decade (2). The total costs associated with long-term care services for these patients have 
been estimated to be £19 billion per year, with an average cost of £28,000 per person, more 
than the costs of cancer or heart disease (3). 
Timely diagnosis of dementia is key because it enables patients to receive early support and 
treatment if necessary, prepare for the future, and benefit from improvements in quality of 
life, while long-term health care costs might be reduced (4). However, many patients with 
dementia in England are not formally diagnosed. In addition, many of those diagnosed are not 
receiving adequate support and treatment to manage their condition.  To address these 
deficiencies in dementia services, national policy makers advocate a model of care centred 
around Memory Assessment Services (MAS, (5)). These ambulatory care memory clinics 
provide an integrated multi-professional approach to diagnostic services and follow up 
dementia care. MAS have become the established and widely adopted model for providing 
services to diagnose and initiate treatment in those with cognitive impairment, although other 
approaches based within primary care have been proposed in a few areas (6, 7). 
There is some limited evidence suggesting that patients referred to MAS in England have a 
better care experience (8) and improved health-related quality of life (HRQL) (9). On the 
other hand, clinical trials in France and Netherlands found few differences in health outcomes 
of patients receiving follow up care by MAS or GPs (10, 11). Importantly, the wide range of 
different models of memory services complicates any comparisons between studies – both 
between and within countries - and may lead to misleading recommendations about the 
relative effectiveness of MAS (12).  
Evidence on the relative costs of diagnostic and post-diagnosis services is also scarce. A 
previous study that focused on a single memory clinic (13) found no difference in costs of 
dementia services provided by MAS compared to community health services. The relative 
cost-effectiveness of MAS in England is not known. A previous modelling study (4) provided 
some cost projections for MAS based on published literature, and suggested that MAS 
needed to achieve only modest gains in patient’s HRQL to be deemed cost-effective. 
A recent multi-centre observational study followed up a large number of patients attending a 
representative sample of MAS in England (14). Using data from this large observational 
study, we have previously reported detailed costs and outcomes associated with MAS (15, 
16). Drawing on the same study, this paper assesses the cost-effectiveness of MAS for the 
diagnosis and follow up care of patients referred with suspected dementia in the first six 
months after diagnosis. We also examine whether the cost-effectiveness of MAS differs 
according to patient subgroups or clinic characteristics. 
Methods 
Study design 
We recruited 80 MAS at random from the 212 memory clinics identified by the Royal 
College of Psychiatrists. Two sites subsequently withdrew, five sites were excluded for 
having recruited fewer than six patients, and four sites were excluded from this analysis after 
failing to collect outcome data at six months, leaving a final sample of 69 MAS. The sample 
was representative of MAS in England, both geographically and in terms of number of 
referrals, waiting times for first appointment and accreditation status. Further details on the 
sample are reported elsewhere (14). The sample reflected the wide diversity of services 
provided by MASs in terms of size, staffing, provision of post-diagnostic support and follow-
up regimes (17). 
Patients with suspected dementia referred for a first appointment at one of the 69 clinics, 
between September 2014 and April 2015, were eligible for inclusion in the study. Patients or 
carers with insufficient English to understand the consent process or study materials (n=43) 
were excluded, resulting in a total sample of 1318 patients. 
Data collection 
Patients and carers completed questionnaires about HRQL of the patient, at the initial 
assessment and at 6-month follow-up. Data on patients’ socio-demographic and clinical 
characteristics were recorded at baseline. Carers also completed a separate questionnaire 
about resource use at baseline, 3 months and 6 months. All eligible participants were 
followed up regardless of the diagnosis they received (whether or not they had dementia). 
MAS were also asked (by email) to complete an organisational survey, with telephone 
follow-up to maximise the response rate. This survey included data on clinic characteristics 
and resource use related to diagnosis, interventions, and follow-up care. 
Health outcomes 
The patient questionnaire included disease-specific (DEMQOL (18)) and generic (EQ-5D-3L 
(19)) HRQL instruments. DEMQOL is a 28-item instrument, where each item is scored on a 
four-point scale, with a higher score indicating better HRQL. Patients’ informal carers 
completed a proxy-reported disease-specific instrument, DEMQOL-Proxy (18), which has 31 
items with responses on the same 4-point scale as DEMQOL. Both DEMQOL and 
DEMQOL-Proxy were scored using an improved scoring algorithm based on modern 
psychometric methods (20). 
The EQ-5D-3L has five items covering different health domains: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. The EQ-5D-3L profiles were combined 
with health state preferences values from the UK general population (19) to give EQ-5D-3L 
utility index scores, anchored on a scale from 0 (death) and 1 (perfect health). Similar to 
DEMQOL, carers also completed a EQ-5D-3L-Proxy, with the same items as patient-
reported EQ-5D-3L. 
Quality-adjusted life years (QALYs) were calculated by valuing each patient’s survival time 
(all patients included in the sample have survived for 6 months) by their EQ-5D-3L score at 
baseline and 6 months according to the ‘area under the curve’ approach. To construct QALYs 
based on DEMQOL, we have derived a preference-based score (DEMQOL-U and 
DEMQOL-Proxy-U) from the original DEMQOL measure, using a previously developed 
algorithm (21).  
Resource use and costs 
The cost analysis took a societal perspective, including costs incurred by health and social 
care providers, the MAS, the patient (out-of-pocket expenses), and the family and/or 
caregiver (informal care). Full details of the resource use and costing approach are reported 
elsewhere (16). Briefly, total MAS costs included diagnostic services, and half (6 months) of 
the annual MAS costs with interventions and follow up care. Patient’s resource use reported 
by the carer included contacts with health care and social care professionals such as GPs, 
nurses, psychologists, psychiatrists and social workers (in the last four weeks). The unit cost 
of each contact was taken from national costs sources (22). Dementia drug costs were 
obtained from the British National Formulary (BNF, 2014). Psychosocial support services 
such as cognitive stimulation, art and music therapies were costed per session, and unit costs 
taken from national sources and related literature (22). Following general guidance for 
valuing informal care in health economic evaluation (23), we included costs related to carer’s 
time valued at £6 per hour based on the national minimum wage for 2013-2014.  
At the clinic level, staff use was valued using unit costs for health and social care 
professionals (22). The costs of imaging and other diagnostic tests were taken from NHS 
reference costs (24). 
Cost-effectiveness 
We assessed the cost-effectiveness of MAS by comparing the 6-month health outcomes 
(HRQL) and costs of patients attending MAS with those that would have occurred had these 
patients not received follow up care by MAS (baseline HRQL and costs). The implicit 
assumption here is that, without MAS attendance, patients’ quality of life and costs would 
remain constant between baseline and 6 months.  
We summarised cost-effectiveness of MAS at 6 months by reporting incremental net 
monetary benefits. These are calculated by valuing the incremental QALY by the willingness 
to pay threshold recommended by NICE (£30,000 per QALY), and subtracting from this the 
incremental cost. We investigated whether the cost-effectiveness of MAS differed according 
to patient subgroups: age, sex, ethnicity, deprivation, and number of comorbidities. Similarly, 
we also assessed cost-effectiveness by clinic characteristics: number of new patients per 
month, number of follow up appointments within the first year, cost of MAS per patient, and 
whether the clinic provided psychosocial support. 
 
 
Statistical analysis 
We estimated mean HRQL at baseline and 6 months across the different HRQL measures. 
Total costs at 6 months included patient-level costs related to health and social care and 
informal care, and clinic-level costs related to diagnostic services, interventions and follow 
up care. Confidence intervals around changes in HRQL, QALY and cost endpoints between 
baseline and 6 months were obtained using non-parametric bootstrapping (1000 replications). 
The base case analysis estimated incremental net benefits at 6 months, assuming that the cost 
and outcomes between baseline and 6 months would have remained the same had the patients 
not attended MAS. Mean differences in the net benefits between subgroups were adjusted for 
patient characteristics, baseline EQ-5D-3L and clustering by clinic (using a multilevel 
regression model). Uncertainty (95% CI) around adjusted differences in the net benefits was 
obtained from the bootstrap samples.  
We conducted sensitivity analysis to assess whether the cost-effectiveness results were 
sensitive to key assumptions in the base case scenario. More specifically, we relaxed the 
assumption that patients’ outcomes and costs would remain constant between baseline and 6 
months without MAS attendance. For example, we estimated cost-effectiveness assuming 
that patients’ HRQL was lower (due to ageing and deteriorating cognitive function) and costs 
were higher (at 6 months compared to baseline) had they not received follow up care by 
MAS. We considered decrements in HRQL of 0.1% (three times the age and gender-related 
HRQL decrement in the general population (25)), 5% and 10%; and patient-level cost 
increments of 5%, 10% and 20%. 
Missing resource use and HRQL data were addressed using multiple imputation (MI) 
assuming that the data were ‘missing at random’ (26), that is conditional on the observed 
baseline patient and MAS characteristics, follow-up process measures and observed 
endpoints. To ensure consistency with the analysis models, we considered a multilevel 
approach to MI (27) to recognise the clustering within clinics. Within each bootstrap 
iteration, we applied the analysis model to the multiple imputed datasets (M=20), combined 
the resultant estimates using Rubin’s rules (26), and obtained uncertainty measures from the 
bootstrap samples as usual. All analyses were undertaken in R. 
Results 
1318 patients and 944 carers were recruited across the 69 MAS. Of those, 826 (63%) and 872 
(66%) patients completed DEMQOL and EQ-5D-3L questionnaires, respectively (Table 1). 
Proxy outcomes (DEMQOL-Proxy and EQ-5D-3L-Proxy) and health and social care costs 
reported by carers were available for only about 50% of the patients partly because 374 
(28%) did not have a carer. Patient and clinic characteristics were mostly complete (Table 1).  
Table 2 reports the main cost components at baseline, 3 and 6 month follow-up. At 6 months, 
patients referred to MAS had higher monthly costs related to social care and informal care 
compared to baseline; mean differences were £53 (95% CI 15 to 96) and £59 (95% CI -36 to 
148), respectively. At the clinic level, assessment costs corresponded to half of the total cost 
of MAS services. According to a societal perspective, the mean total cost up to 6 months was 
£1899 (95% CI 1277, 2539) per patient.  
At 6 months, patients referred to MAS experienced better quality of life compared to baseline 
by reference to all HRQL measures (except EQ-5D-3L-Proxy) (Table 3). For example, mean 
difference in EQ-5D-3L was 0.023 (95% CI 0.008 to 0.038). The incremental net benefit 
based on QALYEQ-5D-3L was -£1724 (95% CI -2388 to -1085), suggesting that the QALY gain 
was relatively small compared to the additional costs. This led to a much higher cost per 
QALY (£374,164) compared to the NICE’s recommended threshold (£30,000 per QALY 
gain). These base-case cost-effectiveness results appeared to be relatively robust to changes 
in the assumptions related to costs and HRQL (Figure 1); the distribution of incremental costs 
and QALYs for most scenarios lay above the recommended willingness-to-pay threshold 
value for a QALY gain. MAS became cost-effective when the patients not referred to MAS 
were assumed to experience 20% higher health and social care costs and 10% lower HRQL at 
6 months (compared to baseline). 
Subgroup analyses according to patient and clinic characteristics are summarised in Figure 2 
and Table 4, respectively. Incremental net benefits are relatively similar across the different 
patient subgroups, with the exception of age (Figure 2). Patients aged 80 or older achieved 
higher gains in QALYs and had lower costs, leading to a higher net monetary benefit 
(adjusted mean difference was £1379, p-value<0.01) compared to younger patients. Table 4 
suggests that MAS with a higher number of new patients per month (more than 75), or lower 
clinic cost (below £2500) per new patient, were relatively more cost-effective (p-
values<0.01), because these tended to be associated with a lower average total cost. In line 
with this, there was some evidence that MAS with a wider range of staff providing 
psychosocial support (reflecting larger MAS) were associated with higher net benefits (mean 
adjusted difference was £629, p-value=0.04). 
Discussion 
Main findings  
Patients referred to MAS with suspected dementia had experienced an improvement in 
quality of life six months after diagnosis, according to both generic and disease-specific 
HRQL measures. However, over this short follow-up period the changes in HRQL were 
relatively small when compared to the costs associated with MAS meaning that this service 
was not cost-effective assuming that a QALY (based on EQ-5D-3L) is valued at £30,000. 
This assessment assumed that patients’ HRQL and costs would have remained constant over 
the 6-month period had they not attended MAS. The sensitivity analysis considered 
alternative assumptions, and suggested that MAS could be cost-effective if, without MAS 
attendance, patients’ HRQL were to deteriorate by about 10% and health and social care costs 
were to increase 20% over the six-month period. Such changes would involve a decrease of 
0.07 in the EQ-5D-3L score (0.71 to 0.64) and an increase in costs (£1543 to £1850) over the 
6 months. These changes are unlikely given the changes observed for ‘usual care’ patients in 
recent clinical trials (10, 28, 29).  
There was little evidence of differences in the cost-effectiveness of MAS between patient 
subgroups, although patients aged over 80 benefit more (greater change in HRQL) from 
referral to MAS. Large clinics (more than 75 new patients per month) appear to benefit from 
economies of scale, but these are not necessarily associated with better HRQL outcomes. 
There was strong evidence that MAS with lower cost per new patient (less than £2500) were 
relatively more cost-effective, regardless of their size. 
Comparison with other studies 
Only one previous study has attempted to determine the cost-effectiveness of MAS in 
England (4). Their model suggested that MAS could be cost-effective if QALY gains per 
person year were between 0.01 and 0.02. This is approximately the level of patient-reported 
QALY gains (based on both EQ-5D-3L and DEMQOL-U) reported in our study. However, 
for these levels of QALY improvement, our results suggest that MAS may not be cost-
effective across alternative, plausible assumptions about the costs of MAS. Our sensitivity 
analysis suggests that QALY gains greater than 0.02 may be required to warrant the costs 
associated with MAS. The differences between the two studies may be related to assumptions 
about the costs. For example, Banerjee and Wittenberg’s projections assumed that MAS 
would lead to cost savings from reduced use of residential care, something that we have not 
considered, as that did not occur in the short time period we considered. In addition, their 
study did not include direct costs of diagnostic investigations, which can be relatively large. 
Two small clinical trials in the Netherlands compared costs and outcomes of post-diagnostic 
care to patients with dementia between MAS and GP services. One study (10) found that 
MAS were not effective or cost-effective compared to GP care. Conversely, the other (single-
centre) trial (29) reported that MAS were cost-effective compared to GP care at 1 year 
(QALY gain was 0.05, incremental cost was €65). However, this was partly related to the fact 
that MAS assessment costs were not included and randomised patients had poor prognosis 
(average baseline EQ-5D-3L was about 0.5), benefitting relatively more from MAS 
compared to ‘usual care’. 
Strengths and limitations 
This study reports a cost-effectiveness analysis of the largest observational study of patients 
referred to MAS in England. Unlike previous studies focussing on a single memory clinic (9, 
13, 28), our results are representative of MAS across all regions in the country (14). This 
economic evaluation is based on rigorous collection of data on different measures of 
effectiveness (both disease-specific and generic HQRL measures reported by patients and 
carers), and costs to the NHS, social care, carers and patients (adopting a societal 
perspective). In addition, this is the first study assessing the relative cost-effectiveness of 
MAS of different ‘types’ of memory services. 
A major limitation of this study is the lack of a comparator, i.e. what would have been 
patients’ costs and outcomes had they not been referred to MAS. Our base case assumption 
was that these patients would have, at 6 months, the same HRQL and costs as they had at 
baseline (first appointment at MAS) had they not been referred. This is plausible as these 
patients were likely to have remained undiagnosed and, hence, received the same level of 
care as before. The literature suggests that there is no change in people’s HRQL over 6-12 
months (30-32). However, in sensitivity analysis we explored departures from this 
assumption. For example assuming higher costs or lower HRQL if patients had not attended a 
MAS suggested that MAS would only be cost-effective over the first six months if 
implausible assumptions are made. 
Our study was prone to missing data, which is typical in studies using self-reported and 
proxy-reported HRQL and resource use questionnaires. We have considered a principled 
approach (multiple imputation) to address the missing values, rather than relying on ad-hoc 
assumptions. This approach assumed that the missing data were unrelated to unobserved 
values, conditional on the observed data, such as baseline patient and MAS characteristics, 
follow-up process measures and observed endpoints. 
Given the large number of MAS included in the study, it was not feasible to undertake a 
micro-costing of each clinic. Instead, the costs were mostly based on staff use in these clinics, 
which crucially depended on the quality of reporting by MAS. This was thoroughly checked 
with local sites and the mean whole-time equivalent (WTE) staff observed was similar to the 
assumption of 10 WTE considered in Banerjee and Wittenberg’s projections (4). In addition, 
our sensitivity analysis suggested that the cost-effectiveness of MAS was relatively robust to 
alternative assumptions about costs.  
An additional limitation was that potential cost savings following referral to MAS, for 
example delayed admission to a care home, were not included in this study. The positive 
cost-effectiveness of MAS presented by Banerjee and colleagues (9) included a 10% 
reduction in care home use. While ignoring such cost savings may have underestimated the 
cost-effectiveness of MAS, such impact was unlikely to occur within the first 6 months after 
diagnosis (we also noted that less than 1% of our sample were care home residents at 
baseline). 
Policy implications and conclusion 
Early diagnosis and treatment of dementia is a priority in many countries. The model of care 
based on MAS improves the HRQL of patients, but the gains over the first six months may 
not be sufficient to warrant the costs involved. Patients in this study are being followed up to 
24 months, which will allow us to examine whether HRQL gains are maintained and/or costs 
reduced in the longer term. In such analyses, assumptions about HRQL deterioration of 
patients not referred to MAS and potential cost savings due to delayed care home admission 
will play an important role in establishing the cost-effectiveness of MAS. The relative cost-
effectiveness of MAS differed according to clinic characteristics, including the number of 
new patients per month, clinic costs per new patient, and availability of psychosocial support. 
One policy challenge is, therefore, to learn from these observed associations so as how to 
improve the efficiency of MAS, particularly those with high average cost. 
Before drawing conclusions from these findings it is also important to recognise that referral 
to MAS is a gateway to a wide range of different consequences. Whilst about 61% of patients 
are likely to receive anti-dementia medication and 22% may take part in psychosocial 
interventions, there is a proportion of patients for whom no discrete action is taken and also 
some (17%) for whom no diagnosis is given (15). Against this background, measures of 
HRQL may not encompass all the potential benefits that patients may obtain from MAS. For 
example, users of these services may welcome and value the reassurance and support that 
staff provide and the knowledge that they are not alone in having to deal with the challenges 
that their dementia symptoms present. Despite the widespread use of EQ-5D-3L and 
DEMQOL, they are designed to measure health-related outcomes (HRQL) rather than other 
experiential benefits or broader wellbeing. In addition, the results  reported here do not 
include any HRQL gains for carers, which would have improved the cost-effectiveness of 
MAS (33). We plan to consider the impact of such benefits in future analyses. 
In conclusion, this study adds important evidence to the debate on the relative value for 
money of MAS for early diagnosis, treatment and follow-up care of patients with suspected 
dementia. Our findings suggest that the relative gains in HRQL may be modest when 
compared to the additional costs of MAS but longer-term evidence is required before drawing 
conclusions about the cost-effectiveness of MAS.  
References 
1. Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: Estimates for 
2009. Alzheimers Dement. 2010;6(2):98-103. 
2. Prince M, Knapp M, Guerchet M, McCrone P, Comas-Herrera A, Wittenberg R, et al. 
Dementia UK: Second edition - Overview. Alzheimer's Society. 2014. 
3. Department of Health. A state of the nation report on dementia care and support in England 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/262139/Dementia
.pdf2013 [cited 2016 October]. 
4. Banerjee S, Wittenberg R. Clinical and cost effectiveness of services for early diagnosis and 
intervention in dementia. Int J Geriatr Psychiatry. 2009;24(7):748-54. 
5. Department of Health. Memory assessment service specifications 
http://dementia.dh.gov.uk/memory-assessment-service-specifications/2011 [cited 2017 April]. 
6. Greening L, Greaves I, Greaves N, Jolley D. Positive thinking on dementia in primary care: 
Gnosall Memory Clinic. Community Pract. 2009;82(5):20-3. 
7. Lee L, Hillier LM, Stolee P, Heckman G, Gagnon M, McAiney CA, et al. Enhancing dementia 
care: a primary care-based memory clinic. J Am Geriatr Soc. 2010;58(11):2197-204. 
8. Hailey E, Hodge S, Burns A, Orrell M. Patients' and carers' experiences of UK memory 
services. Int J Geriatr Psychiatry. 2016;31(6):676-80. 
9. Banerjee S, Willis R, Matthews D, Contell F, Chan J, Murray J. Improving the quality of care 
for mild to moderate dementia: an evaluation of the Croydon Memory Service Model. Int J Geriatr 
Psychiatry. 2007;22(8):782-8. 
10. Meeuwsen E, Melis R, van der Aa G, Goluke-Willemse G, de Leest B, van Raak F, et al. Cost-
effectiveness of one year dementia follow-up care by memory clinics or general practitioners: 
economic evaluation of a randomised controlled trial. PLoS One. 2013;8(11):e79797. 
11. Nourhashemi F, Andrieu S, Gillette-Guyonnet S, Giraudeau B, Cantet C, Coley N, et al. 
Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial 
(PLASA study). BMJ. 2010;340:c2466. 
12. Banerjee S. A narrative review of evidence for the provision of memory services. Int 
Psychogeriatr. 2015;27(10):1583-92. 
13. Rubinsztein JS, van Rensburg MJ, Al-Salihy Z, Girling D, Lafortune L, Radhakrishnan M, et al. A 
memory clinic v. traditional community mental health team service: comparison of costs and quality. 
BJPsych Bull. 2015;39(1):6-11. 
14. Park M, Smith SC, Neuburger J, Chrysanthaki T, Hendriks J, Black N. Socio-demographic 
characteristics, cognitive function and health-related quality of life of patients referred to Memory 
Assessment Services in England Alzheimer Disease and Associated Disorders. 2016;(In press). 
15. Park M, Smith SC, Chrysanthaki T, Neuburger J, Ritchie C, Hendriks J, et al. Change in health-
related quality of life of patients at 6 months after referral to Memory Assessment Services. 
Alzheimer Disease and Associated Disorders. 2016;(In press). 
16. Pennington M, Gomes M, Chrysanthaki T, Hendriks J, Wittenberg R, Knapp M, et al. The cost 
of diagnosis and early support in patients with cognitive decline. (In press). 2016. 
17. Chrysanthaki T, Fernandes B, Smith S, Black N. Can Memory Assessment Services (MAS) in 
England be categorized? A national survey. J Public Health (Oxf). 2017:1-13. 
18. Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, et al. Measurement of 
health-related quality of life for people with dementia: development of a new instrument (DEMQOL) 
and an evaluation of current methodology. Health Technol Assess. 2005;9(10):1-93, iii-iv. 
19. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. 
Health Policy. 1990;16(3):199-208. 
20. Smith SC, Hendriks J, Chrysanthaki T, Cano S, Black N. How can we interpret proxy reports of 
HRQL when it is no longer possible to obtain a self-report? ISOQOL. 2015; 22nd Annual 
conference:Vancouver, Canada. 
21. Mulhern B, Rowen D, Brazier J, Smith S, Romeo R, Tait R, et al. Development of DEMQOL-U 
and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY 
for use in economic evaluation. Health Technol Assess. 2013;17(5):v-xv, 1-140. 
22. Curtis L. Unit costs of health and social care http://www.pssru.ac.uk/project-pages/unit-
costs/2014/: Personal Social Services Research Unit; 2014 [cited 2016 October ]. 
23. Koopmanschap MA, van Exel JN, van den Berg B, Brouwer WB. An overview of methods and 
applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics. 
2008;26(4):269-80. 
24. Department of Health. NHS Reference Costs 2013 to 2014 
https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-20142014 [cited 2016 
October]. 
25. Ara R, Brazier JE. Populating an economic model with health state utility values: moving 
toward better practice. Value Health. 2010;13(5):509-18. 
26. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: Wiley; 1987. 
27. van Buuren S. Multiple Imputation of Multilevel Data. In: Hox J, Roberts K, editors. The 
Handbook of Advanced Multilevel Analysis. Milton Park, UK: Routledge; 2010. 
28. Tanajewski L, Franklin M, Gkountouras G, Berdunov V, Harwood RH, Goldberg SE, et al. 
Economic Evaluation of a General Hospital Unit for Older People with Delirium and Dementia (TEAM 
Randomised Controlled Trial). PLoS One. 2015;10(12):e0140662. 
29. Wolfs CA, Dirksen CD, Kessels A, Severens JL, Verhey FR. Economic evaluation of an 
integrated diagnostic approach for psychogeriatric patients: results of a randomized controlled trial. 
Arch Gen Psychiatry. 2009;66(3):313-23. 
30. Hoe J, Hancock G, Livingston G, Woods B, Challis D, Orrell M. Changes in the quality of life of 
people with dementia living in care homes. Alzheimer Dis Assoc Disord. 2009;23(3):285-90. 
31. Selwood A, Thorgrimsen L, Orrell M. Quality of life in dementia--a one-year follow-up study. 
Int J Geriatr Psychiatry. 2005;20(3):232-7. 
32. Sheehan B, Lall R, Gage H, Holland C, Katz J, Mitchell K. A 12-month follow-up study of 
people with dementia referred to general hospital liaison psychiatry services. Age Ageing. 
2013;42(6):786-90. 
33. Al-Janabi H, Flynn TN, Coast J. QALYs and carers. Pharmacoeconomics. 2011;29(12):1015-23. 
 
